PharmaResearch Bio Co Ltd

PharmaResearch Bio Co Ltd maintains a debt-to-equity ratio of 0.6, indicating a relatively conservative capital structure. The company's current ratio of 1.09 suggests moderate liquidity, with current assets slightly exceeding current liabilities. However, the free cash flow is negative at -640.6 million KRW, and operating cash flow is 13.4 billion KRW, indicating that capital expenditures are outpacing cash generation. The company's profitability is strong, with a return on equity (ROE) of 21.4% and a return on assets (ROA) of 11.8%. These figures exceed the typical thresholds for the biotechnology and medical research industry, suggesting efficient use of equity and assets. The gross profit margin is 70.1%, and the operating margin is 44.2%, both of which are robust for a company in the pharmaceuticals and medical research sector. PharmaResearch Bio Co Ltd's revenue is concentrated in the domestic market and select international markets, including China and the United Kingdom. The company does not disclose segment-specific revenue, but its geographic exposure is limited to a few key regions, which may increase its vulnerability to regional economic or regulatory shifts. The company's revenue growth is expected to remain stable, with a projected increase in the current fiscal year and a moderate increase in the following year. The capital expenditure of -14.6 billion KRW indicates significant investment in infrastructure or R&D, which may support long-term growth. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could affect its ability to fund operations without external financing. However, the dilution risk is low, suggesting that the company is not likely to issue additional shares in the near term. Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and maintaining its competitive position in the botulinum toxin market. The company has not disclosed any major legal or regulatory issues, and its financial statements show no signs of material misstatements or fraud.